alemtuzumab induction immunosuppressive regimen

Half of the transplant recipients on the belatacept-sirolimus regimen developed transient BK viremia within the first year, suggesting disproportionate impairment of anti-BK virus immunity, although a

Effect: adverse; 10/20 patients (50%) developed transient BK viremia

Half of the transplant recipients on the belatacept-sirolimus regimen developed transient BK viremia within the first year, suggesting disproportionate impairment of anti-BK virus immunity, although a

Effect: adverse; 10/20 patients (50%) developed transient BK viremia

Half of the transplant recipients on the belatacept-sirolimus regimen developed transient BK viremia within the first year, suggesting disproportionate impairment of anti-BK virus immunity, although a

Effect: adverse; 10/20 patients (50%) developed transient BK viremia

Half of the transplant recipients on the belatacept-sirolimus regimen developed transient BK viremia within the first year, suggesting disproportionate impairment of anti-BK virus immunity, although a

Effect: adverse; 10/20 patients (50%) developed transient BK viremia

Half of the transplant recipients on the belatacept-sirolimus regimen developed transient BK viremia within the first year, suggesting disproportionate impairment of anti-BK virus immunity, although a

Effect: adverse; 10/20 patients (50%) developed transient BK viremia

Half of the transplant recipients on the belatacept-sirolimus regimen developed transient BK viremia within the first year, suggesting disproportionate impairment of anti-BK virus immunity, although a

Effect: adverse; 10/20 patients (50%) developed transient BK viremia

Half of the transplant recipients on the belatacept-sirolimus regimen developed transient BK viremia within the first year, suggesting disproportionate impairment of anti-BK virus immunity, although a

Effect: adverse; 10/20 patients (50%) developed transient BK viremia

Half of the transplant recipients on the belatacept-sirolimus regimen developed transient BK viremia within the first year, suggesting disproportionate impairment of anti-BK virus immunity, although a

Effect: adverse; 10/20 patients (50%) developed transient BK viremia

Half of the transplant recipients on the belatacept-sirolimus regimen developed transient BK viremia within the first year, suggesting disproportionate impairment of anti-BK virus immunity, although a

Effect: adverse; 10/20 patients (50%) developed transient BK viremia

Half of the transplant recipients on the belatacept-sirolimus regimen developed transient BK viremia within the first year, suggesting disproportionate impairment of anti-BK virus immunity, although a

Effect: adverse; 10/20 patients (50%) developed transient BK viremia

Half of the transplant recipients on the belatacept-sirolimus regimen developed transient BK viremia within the first year, suggesting disproportionate impairment of anti-BK virus immunity, although a

Effect: adverse; 10/20 patients (50%) developed transient BK viremia

Half of the transplant recipients on the belatacept-sirolimus regimen developed transient BK viremia within the first year, suggesting disproportionate impairment of anti-BK virus immunity, although a

Effect: adverse; 10/20 patients (50%) developed transient BK viremia

Half of the transplant recipients on the belatacept-sirolimus regimen developed transient BK viremia within the first year, suggesting disproportionate impairment of anti-BK virus immunity, although a

Effect: adverse; 10/20 patients (50%) developed transient BK viremia

Half of the transplant recipients on the belatacept-sirolimus regimen developed transient BK viremia within the first year, suggesting disproportionate impairment of anti-BK virus immunity, although a

Effect: adverse; 10/20 patients (50%) developed transient BK viremia

Half of the transplant recipients on the belatacept-sirolimus regimen developed transient BK viremia within the first year, suggesting disproportionate impairment of anti-BK virus immunity, although a

Effect: adverse; 10/20 patients (50%) developed transient BK viremia

Half of the transplant recipients on the belatacept-sirolimus regimen developed transient BK viremia within the first year, suggesting disproportionate impairment of anti-BK virus immunity, although a

Effect: adverse; 10/20 patients (50%) developed transient BK viremia

Half of the transplant recipients on the belatacept-sirolimus regimen developed transient BK viremia within the first year, suggesting disproportionate impairment of anti-BK virus immunity, although a

Effect: adverse; 10/20 patients (50%) developed transient BK viremia

Half of the transplant recipients on the belatacept-sirolimus regimen developed transient BK viremia within the first year, suggesting disproportionate impairment of anti-BK virus immunity, although a

Effect: adverse; 10/20 patients (50%) developed transient BK viremia

Half of the transplant recipients on the belatacept-sirolimus regimen developed transient BK viremia within the first year, suggesting disproportionate impairment of anti-BK virus immunity, although a

Effect: adverse; 10/20 patients (50%) developed transient BK viremia

Half of the transplant recipients on the belatacept-sirolimus regimen developed transient BK viremia within the first year, suggesting disproportionate impairment of anti-BK virus immunity, although a

Effect: adverse; 10/20 patients (50%) developed transient BK viremia

Half of the transplant recipients on the belatacept-sirolimus regimen developed transient BK viremia within the first year, suggesting disproportionate impairment of anti-BK virus immunity, although a

Effect: adverse; 10/20 patients (50%) developed transient BK viremia

Half of the transplant recipients on the belatacept-sirolimus regimen developed transient BK viremia within the first year, suggesting disproportionate impairment of anti-BK virus immunity, although a

Effect: adverse; 10/20 patients (50%) developed transient BK viremia

Half of the transplant recipients on the belatacept-sirolimus regimen developed transient BK viremia within the first year, suggesting disproportionate impairment of anti-BK virus immunity, although a

Effect: adverse; 10/20 patients (50%) developed transient BK viremia

Half of the transplant recipients on the belatacept-sirolimus regimen developed transient BK viremia within the first year, suggesting disproportionate impairment of anti-BK virus immunity, although a

Effect: adverse; 10/20 patients (50%) developed transient BK viremia

Half of the transplant recipients on the belatacept-sirolimus regimen developed transient BK viremia within the first year, suggesting disproportionate impairment of anti-BK virus immunity, although a

Effect: adverse; 10/20 patients (50%) developed transient BK viremia

Half of the transplant recipients on the belatacept-sirolimus regimen developed transient BK viremia within the first year, suggesting disproportionate impairment of anti-BK virus immunity, although a

Effect: adverse; 10/20 patients (50%) developed transient BK viremia

Half of the transplant recipients on the belatacept-sirolimus regimen developed transient BK viremia within the first year, suggesting disproportionate impairment of anti-BK virus immunity, although a

Effect: adverse; 10/20 patients (50%) developed transient BK viremia